Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study

Li, Jielang; Xu, Huanji; Zou, Jiahuan; Wang, Xin; Li, Zhiping; Shen, Yali

doi:10.1080/00365521.2021.1879250

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were reported in the RTOG 98–11 study with higher hematologic grade 3 or 4 toxicity in the FU/MMC arm compared with the FU/DDP arm (61.8% vs. 42%) 25 . Therefore, the mainstream chemotherapy regimens were PF and docetaxel plus cisplatin (TP) in China 15,26,27 . A long‐term result revealed that the actuarial 10‐year OS and DFS rates for the PF group were equivalent to the 5‐fluorouracil plus MMC (MF) group (OS 54% vs. 52%, p = 0.32, DFS 49% vs. 53%, p = 0.92) 28 .…”

Section: Discussionsupporting

confidence: 72%

“…Lu Y et al reported the clinical and epidemiological characteristics of 144 ASCC patients from multicenter in Southern China after 2007 as we mentioned before 15 . Li J et al evaluated the efficacy and safety of DDP/capecitabine (XP) with intensity‐modulated radiation therapy (IMRT) in 11 ASCC patients in Southwest China from January 2017 to June 2019 26 . In our study, we collected all the cases admitted since the establishment of our center, and analyzed the treatment and survival of all patients in detail.…”

Section: Discussionmentioning

confidence: 99%

“… 25 Therefore, the mainstream chemotherapy regimens were PF and docetaxel plus cisplatin (TP) in China. 15 , 26 , 27 A long‐term result revealed that the actuarial 10‐year OS and DFS rates for the PF group were equivalent to the 5‐fluorouracil plus MMC (MF) group (OS 54% vs. 52%, p = 0.32, DFS 49% vs. 53%, p = 0.92). 28 Meanwhile, the 5‐year cumulative colostomy rate was not significantly different between the PF group and the MF group (22% vs. 29%; p = 0.28).…”

Section: Discussionmentioning

confidence: 99%

“… 15 Li J et al evaluated the efficacy and safety of DDP/capecitabine (XP) with intensity‐modulated radiation therapy (IMRT) in 11 ASCC patients in Southwest China from January 2017 to June 2019. 26 In our study, we collected all the cases admitted since the establishment of our center, and analyzed the treatment and survival of all patients in detail. The 5‐year OS and PFS rates for all patients were 63.6%, and 57.3%.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China

Yuan

Xie

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Background Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. Methods This study retrospectively included 59 patients with ASCC admitted from 1975 to 2018 in Sun Yat‐sen University cancer center. The clinical records and follow‐up information of all patients were collected. Survival analysis and univariate and multivariate regression analyses were performed using the “survival” and “survminer” packages of R software. Results In 59 patients, 5 patients had distant metastasis at diagnosis. Among 54 M0 stage patients, 33 patients received chemoradiotherapy (CRT), 19 patients received local surgery, and 2 patients refused curative treatment and received the best supportive treatment (BST). The most common grade 3–4 acute toxicities during treatment were myelosuppression and radiation dermatitis. The median follow‐up time was 32 months. For the whole group, the 3‐year and 5‐year overall survival (OS) rates and disease‐free survival (DFS) were 71.1% and 63.6%, and 73.4% and 69.0%, respectively. Multivariate regression analysis showed that the T3–4 stage was an independent prognostic risk factor for OS, progression‐free survival (PFS), and DFS. And M1 was an independent prognostic risk factor for PFS and DFS. Patients in stage M0 mainly treated with CRT had better local control than those mainly treated with surgery (p = 0.027). For M0 patients, induction chemotherapy combined with CRT tends to prolong OS compared with CRT alone (p = 0.26). The 3‐year colostomy‐free survival for the whole group was 81.1%. Conclusions CRT is recommended as the first choice for the treatment of M0 stage ASCC. Induction chemotherapy may bring better survival benefits for some patients. Patients with ASCC in China seem to have a better local control rate, which suggested different treatment strategies may be needed in China.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 99%